Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism
- PMID: 14709834
- DOI: 10.1507/endocrj.50.657
Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism
Abstract
Bone turnover is reported to increase in favour of resorption in overt hyperthyroidism and the rate of resorption is associated with the levels of thyroid hormones. Hypothyroidism, on the other hand, was shown to cause no disturbance of calcium kinetics and found to associate lower trabecular resorption surfaces and increased bone cortical thickness. Similar studies are very rare in subclinical thyroid disorders and consequently we aimed to examine calcium and bone metabolism in subclinical thyroid disorders. Thirteen patients with subclinical hyperthyroidism secondary to untreated Graves' disease, 20 patients with subclinical hypothyroidism and 10 healthy subjects participated in this survey. Briefly calcium, phosphorus, and creatinine (Cre), urinary deoxypyridinoline (U-DPD) and serum osteocalcin (OC) were measured as biochemical markers for calcium metabolism. Concerning serum Ca and phosphorus levels, there were no differences between three of the groups, but urinary Ca excretion was higher in subclinical hyperthyroid patients compared to control and hypothyroid subjects. Hypothyroid patients had similar U-DPD levels with control subjects (p = 0.218). Serum OC and U-DPD were higher in subclinical hyperthyroid compared to control subjects (p<0.001 and p<0.001 respectively). We demonstrated a higher bone turnover and greater calcium excretion in subclinical hyperthyroid patients. Additionally, we found that subclinical hypothyroidism is not associated with disturbed calcium metabolism. As persistent increase in bone turnover is responsible for accelerated bone loss, patients with Graves' disease may have increased risk for osteoporosis.
Similar articles
-
Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.J Clin Endocrinol Metab. 2000 Nov;85(11):4157-61. doi: 10.1210/jcem.85.11.6979. J Clin Endocrinol Metab. 2000. PMID: 11095447
-
Bone remodelling markers and serum cytokines in patients with hyperthyroidism.Clin Endocrinol (Oxf). 2002 Jul;57(1):125-9. doi: 10.1046/j.1365-2265.2002.01578.x. Clin Endocrinol (Oxf). 2002. PMID: 12100080
-
Early changes in parameters of bone and mineral metabolism during therapy for hyper- and hypothyroidism.Endocr Res. 2001 Feb-May;27(1-2):203-13. doi: 10.1081/erc-100107181. Endocr Res. 2001. PMID: 11428712
-
[Graves' disease and bone metabolism].Nihon Rinsho. 2006 Dec;64(12):2317-22. Nihon Rinsho. 2006. PMID: 17154099 Review. Japanese.
-
Thyroid hormones: beneficial or deleterious for bone?Calcif Tissue Int. 2003 Sep;73(3):205-9. doi: 10.1007/s00223-002-0027-8. Calcif Tissue Int. 2003. PMID: 14667131 Review.
Cited by
-
Thyroid-stimulating hormone, thyroid hormones, and bone loss.Curr Osteoporos Rep. 2009 Jul;7(2):47-52. doi: 10.1007/s11914-009-0009-0. Curr Osteoporos Rep. 2009. PMID: 19631028
-
An explanatory randomised placebo controlled trial of levothyroxine supplementation for babies born <28 weeks' gestation: results of the TIPIT trial.Trials. 2013 Jul 11;14:211. doi: 10.1186/1745-6215-14-211. Trials. 2013. PMID: 23841945 Free PMC article. Clinical Trial.
-
Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men.BMC Endocr Disord. 2011 Aug 6;11:15. doi: 10.1186/1472-6823-11-15. BMC Endocr Disord. 2011. PMID: 21819612 Free PMC article.
-
Skeletal health in patients with differentiated thyroid carcinoma.J Endocrinol Invest. 2021 Mar;44(3):431-442. doi: 10.1007/s40618-020-01359-6. Epub 2020 Jul 21. J Endocrinol Invest. 2021. PMID: 32696339 Review.
-
ENA Actimineral Resource A restores bone loss and bone quality in ovariectomized rats.Mol Cell Biochem. 2007 Jan;295(1-2):35-43. doi: 10.1007/s11010-006-9269-5. Epub 2006 Jul 13. Mol Cell Biochem. 2007. PMID: 16838105
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials